In this (audio only) podcast, two doctors discuss the results of the Phase 3 ASPEN trial, which compared the efficacy and safety of zanubrutinib with that of ibrutinib.  But the second doctor is Dr. Carolyn Owen, Hematologist and Associate Professor of Hematology in Calgary.  She speaks (from about the 20:40 point onward), and includes comments on the challenges of accessing BTKi’s in Alberta (and by extension, many provinces in Canada) and the rationale for the typical prescribing pattern for WM patients: BR first, and then BTKi’s.